170 related articles for article (PubMed ID: 31918330)
1. Effects of Immunosuppressive Medications on Mitochondrial Function.
Nash A; Samoylova M; Leuthner T; Zhu M; Lin L; Meyer JN; Brennan TV
J Surg Res; 2020 May; 249():50-57. PubMed ID: 31918330
[TBL] [Abstract][Full Text] [Related]
2. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function.
Jeanmart H; Malo O; Carrier M; Nickner C; Desjardins N; Perrault LP
J Heart Lung Transplant; 2002 Sep; 21(9):990-8. PubMed ID: 12231370
[TBL] [Abstract][Full Text] [Related]
5. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
[TBL] [Abstract][Full Text] [Related]
8. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients.
Silva HT; Yang HC; Abouljoud M; Kuo PC; Wisemandle K; Bhattacharya P; Dhadda S; Holman J; Fitzsimmons W; First MR
Am J Transplant; 2007 Mar; 7(3):595-608. PubMed ID: 17217442
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of immunosuppressive regimens in renal transplantation.
Guerra G; Ciancio G; Gaynor JJ; Zarak A; Brown R; Hanson L; Sageshima J; Roth D; Chen L; Kupin W; Tueros L; Ruiz P; Livingstone AS; Burke GW
J Am Soc Nephrol; 2011 Sep; 22(9):1758-68. PubMed ID: 21807891
[TBL] [Abstract][Full Text] [Related]
12. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
[TBL] [Abstract][Full Text] [Related]
15. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
[TBL] [Abstract][Full Text] [Related]
18. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.
Kurata K; Yakushijin K; Okamura A; Yamamori M; Ichikawa H; Sakai R; Mizutani Y; Kakiuchi S; Miyata Y; Kitao A; Kawamoto S; Matsuoka H; Murayama T; Minami H
Cancer Chemother Pharmacol; 2018 May; 81(5):839-846. PubMed ID: 29511796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]